arrow
G

Gaston De Serres

Laval University
H指数:67
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety of co-administration of COVID-19 and seasonal influenza vaccines in individuals with autoimmune diseases from the Canadian National Vaccine Safety Network

加拿大国家疫苗安全网络关于自身免疫性疾病患者同时接种COVID-19和季节性流感疫苗的安全性研究

2025-12-310
PRE
The Canadian National Vaccine Safety (CANVAS) network: Cross-sectional analysis of seasonal influenza vaccine safety in children during the 2013/2014 to 2019/2020 influenza seasons

加拿大国家疫苗安全(CANVAS)网络:2013/2014至2019/2020流感季儿童季节性流感疫苗安全性横断面分析

vaccine
IF2.2
2025-08-260
OAAI
Long COVID risk and severity after COVID-19 infections and reinfections: a retrospective cohort study among healthcare workers

COVID-19感染及再感染后的长新冠风险与严重程度:一项在医疗保健工作者中的回顾性队列研究

2025-08-070
OAAI
What is the current evidence base for measles vaccination earlier than 9 months of age?: Report from an informal technical consultation of the World Health Organization

当前麻疹疫苗接种时间早于9个月年龄的证据基础是什么?:世界卫生组织非正式技术咨询会议报告

VACCINE
IF3.5
2025-05-010
PRE
mRNA COVID-19 vaccine safety among children and adolescents: a Canadian National Vaccine Safety Network cohort study

mRNA新型冠状病毒肺炎儿童和青少年的疫苗安全性: 加拿大国家疫苗安全网络队列研究

2024-12-011
OAAI
Impact of recruitment strategies on individual participation practices in the Canadian National Vaccine Safety Network: prospective cohort study

招募策略对加拿大国家疫苗安全网络中个人参与实践的影响: 前瞻性队列研究

2024-08-121
OAAI
A multiprovincial retrospective analysis of the incidence of myocarditis or pericarditis after mRNA vaccination compared to the incidence after SARS-CoV-2 infection
HELIYON
IF3.6
2024-03-010
OAAI
Single-dose Effectiveness of mpox Vaccine in Quebec, Canada: Test-negative Design With and Without Adjustment for Self-reported Exposure Risk

加拿大魁北克mpox疫苗的单剂量有效性: 测试阴性设计,是否对自我报告的暴露风险进行了调整

2023-09-2814
OAAI
Infection-induced seroconversion and seroprevalence of SARS-CoV-2 among a cohort of children and youth in Montreal, Canada

在加拿大蒙特利尔的一组儿童和青少年中,感染引起的血清转化和SARS-CoV-2血清阳性率

2023-08-253
OAAI
Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study
2023-01-0159
OAAI
Spike recognition and neutralization of SARS-CoV-2 Omicron subvariants elicited after the third dose of mRNA vaccine
2023-01-0117
OAAI